NanoViricides Inc. (NNVC)

[changes_iv]

WASHINGTON (Reuters) - A surgeon infected with Ebola in Sierra Leone will be flown to the University of Nebraska Medical Center for treatment, "CBS Evening News" reported on Thursday.

The surgeon was born in Sierra Leone but is a U.S. resident, CBS reported.

University of Nebraska Medical Center officials declined to confirm the report but said in a statement that a patient who contracted the disease in Sierra Leone was being evaluated for possible treatment at the hospital.

"He will be evaluated by the medical crew on the Phoenix Air jet upon their arrival in Sierra Leone," the hospital said. "The members of the crew will determine whether the patient is stable enough for transport - if he is, he would arrive in Omaha sometime Saturday afternoon."

The EbolaCide2 dose will be 5 cc's (~1 teaspoon). The 5 cc minimum feasible dose has been estimated to be best and enough to strike the killer Ebola virus in the host. The cGMP Pilot Plant in Shelton CT, once validated, will be capable of making 1000 doses/batch of EbolaCide2.

What is and why an intramuscular injection?

What are Intramuscular Injections?

An intramuscular injection is a technique used to deliver a medication deep into the muscles. This allows the medication to be absorbed into the bloodstream quickly. You may have received an intramuscular injection at a doctor’s office the last time you got a vaccine, like the flu shot.

What are Intramuscular Injections Used For?

Intramuscular injections are used to deliver drugs and vaccines. They are a common practice in modern medicine. Several drugs and almost all inactivated vaccines are delivered this way.

Intramuscular injections are used when other types of delivery methods are not recommended. These include oral (swallowed into the stomach), intravenous (injected into the vein), and subcutaneous (injected just under the layer of skin).

The speed of absorption is faster for intramuscular injection compared to subcutaneous injection. This is because the muscle tissue has a greater blood supply than the area just under the skin. Muscle tissue may also hold a larger volume of medication than subcutaneous tissue.

Intramuscular injection may be used instead of intravenous injection because some drugs are irritating to veins. Sometimes, a suitable vein cannot be located. It may be used instead of oral delivery because some drugs are destroyed by the digestive system when a drug is swallowed

http://www.healthline.com/health/intramuscular-injection#Purpose2

"We believe the new anti-Ebola ligands should make the new drug candidates substantially superior to our older ones, based on the molecular modeling studies we have conducted using the structural information of interaction of Ebola virus glycoprotein with its cellular receptor Niemann-Pick C1 protein," said Anil R. Diwan, PhD, President of the Company, "We believe that Ebola virus will not be able to avoid our drug candidates in spite of mutations, because we are mimicking NPC1, the receptor to which the virus must bind in order to infect the host cell. Of course, we must await results from actual cell culture and animal testing to further develop these candidates."
.
.
.
NanoViricides, Inc. now has the capability of producing sufficient quantities of an anti-Ebola drug, after it is developed, for combating current and future Ebola epidemics. The highly customizable nanomedicine cGMP capable pilot scale manufacturing facility in Shelton, CT, will be able to supply all of the nanoviricides drug candidates in quantities needed for human clinical trials.
.
.
.
As of September 5, 2014, the World Health Organization (WHO) and the Centers for Disease Control (CDC) reported a total of 3,967 suspected cases and 2,105 deaths, according to Wikipedia (en.wikipedia.org/wiki/Ebola_virus_epidemic_in_West_Africa). WHO has reported an overall case fatality rate estimate of 52%, considerably lower than that reported from previous outbreaks. Unfortunately, this Ebola outbreak has continued to expand at an exponential rate in spite of significant efforts to contain it.

Currently, there are no approved drugs or vaccines against Ebola, although some vaccines as well as some drug candidates have entered clinical trials. Recently, WHO has announced a policy for use of experimental drugs against Ebola to expedite drug availability.

http://www.nanoviricides.com/press%20releases/2014/NanoViricides%20Reports%20That%20It%20Has%20Designed%20and%20Commenced%20Synthesis%20of%20Novel%20Ebola%20Drug%20Candidates.html

A human host to any virus has approximately 100 trillion cells. A 5 cc (minimum feasible ~ 1 teaspoon) dose has approximately 75 trillion of EbolaCide2/nanoviricides (nanobots), that once injected intramuscular, will be quickly moving in the host's bloodstream to clash in the trillions with the Ebola virus structures, destroy the rising tide of Ebola virus structures in the trillions and in a matter of hours. Why is this important? If EbolaCide2 clashes and destroys the virus in the trillions, in a matter of hours, the cytokine storm is averted or quickly degraded. The Ebola virus host immune system has then an easier task to fight the murderous infection while the Ebolacide2 nanobots will continue their search of Ebola virus structures for an estimated 30 days after the EbolaCide2 drug was administered.

Why the Ebola virus is so deadly

It is not the virus that directly causes the infamous bleeding. Yes, the virus attacks different organs as well as the immune system, but the most serious problem is a severe over-reaction by our own immune system, called a cytokine storm. This causes blood clotting in all the wrong places, called disseminated intravascular coagulation,24 which damages organs such as the liver. Also, this uses up all the blood clotting factors, meaning that clots won’t form where they should, resulting in uncontrollable bleeding.25,26 It’s notable that the deadliest epidemic of Ebola’s fellow negative-sense–RNA virus influenza also caused cytokine storms. This is why the pandemic killed so many previously healthy people—they had the strongest immune systems, and these were turned against them. In the case of influenza, the immune system severely inflamed the patient’s lungs.27

At present there is no cure or vaccine for Ebola. Treatment involves rehydration, pain relief, and pro-coagulants to control bleeding. Also, there is blood transfusion to replace loss, as well as blood plasma from Ebola survivors containing antibodies that could fight the disease. Indeed, Dr Brantly was helped by a 14-year-old former patient’s transfusion, and he has since donated blood plasma to other sufferers.28

http://creation.com/ebola-fall

The out-of-control Ebola virus has short-circuit the government's FDA track of obstacles or steeplechase race and turn it into a fast track for small biotechs like NanoViricides, Inc. that are unafraid to take on the challenge. NanoViricides, Inc. has not been travelling for years to now shy away from engaging in battle with a human killing virus.

EbolaCide2 candidates will soon be at the USAMRIID bsl-4 facilities to engage. EbolaCide2 is armed with dramatically superior ligands, it is low-toxicity, life-saving and fast-acting. Using our platform technology, NanoViricides, Inc. has developed novel drug EbolaCide2. Who are you betting on, the Ebola virus or NanoViricides, Inc. novel drug EbolaCide2?

==============================================

“This isn't about going back, it's about life being ahead of you and you run at it! Because you never know how far you can go unless you run.” ? Penny Chenery, owner of the "Flying Horse" Secretariat